• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Actelion, J&J re-enter takeover negotations

December 21, 2016 By Sarah Faulkner

Actelion, J&J re-enter takeover negotationsActelion (VTX:ATLN) and Johnson & Johnson (NYSE:JNJ) have re-entered talks to reach a takeover deal, after the US healthcare giant reportedly abandoned its efforts last week. Some suggest that this could mean the end of Sanofi‘s (NYSE:SNY) attempt to make a deal with the Swiss biotech firm, according to Reuters. 

J&J and Actelion had been engaged in informal talks for nearly 2 months and J&J’s initial offer was valued at 250 Swiss francs per share before the company backed out. Actelion has a market value of 23.2 billion Swiss francs, nearly $23 billion USD. ATLN shares were trading at 215 Swiss francs per share in afternoon trading activity today, up 6.5%.

French drugmaker Sanofi reportedly stepped in to pursue negotiations with Actelion last week. The company is on the hunt for a deal ever since it lost a bid for Medivation to Pfizer’s $14 billion offer in August. Analysts said Sanofi CEO Olivier Brandicourt cannot afford to fail in a 2nd high-profile bid, Reuters reported.

Actelion CEO Jean-Paul Clozel has made efforts to maintain the company’s independence, like in 2011 when he rallied shareholders against a hedge fund’s attempt to sell the firm.

“It wasn’t about price, he simply doesn’t want to give up control,” a source close to J&J told Reuters when the company backed out of talks last week.

In response to the latest development, Actelion said there “can be no assurance any transaction will result from these discussions.”

Filed Under: Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS